

NICOLA STURGEON, FIRST MINISTER OF SCOTLAND, OPENS REPROCELL EUROPEAN HEADQUARTERS IN GLASGOW

Location: REPROCELL Europe Ltd. (Glasgow, UK)
Business Unit: REPROCELL Discovery
Date: August 10, 2017

Announcement — REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK. The REPROCELL Centre for Predictive Drug Discovery at West of Scotland Science Park was inaugurated by Scotland's First Minister, Nicola Sturgeon. The new headquarters will enable the company to strengthen its pharmaceutical industry-targeted drug discovery services and translational research, and generate new employment opportunities in Scotland.

The company's relocation to the West of Scotland Science Park was supported by £150,000 of Regional Selective Assistance from Scottish Enterprise in December 2016. Since then, REPROCELL has invested a further £630,000 to expand its European headquarters and develop its product and service offering.

REPROCELL has expertise in the development of predictive assays using stem cells, 3D tissue models and fresh human tissues, which offer the pharmaceutical industry novel tools for investigating the safety and efficacy of new drug candidates early in the drug discovery process. The Centre for Predictive Drug Discovery will allow the company to continue to develop these lines of business by growing its Glasgow-based workforce and expand operations to focus on the launch of new services.

Commenting on the company's new Scottish headquarters Nicola Sturgeon, First Minister of Scotland said: "Life sciences is an exciting and developing growth sector for Scotland's economy and it is testament to confidence in the sector that REPROCELL has decided to base its European operations here. The jobs that are being created and safeguarded will provide significant benefit to the surrounding area and I am looking forward to seeing the company go from strength to strength in the future."

Dr David Bunton, CEO of REPROCELL Europe Ltd said: "Scottish Enterprise has worked closely with the company in Scotland, Europe, US and Japan to provide business support. This has included work from SDI field colleagues in Japan and across Europe to help identify potential customers, as well as tailored company support on the ground in Scotland to look at new market opportunities globally and extend existing testing services."

Rhona Allison, Company Growth Senior Director at Scottish Enterprise, said: "REPROCELL's new expertise in stem-cell reprogramming and 3D cell culture, together with its world class

facilities are a further and significant boost to Scotland's growing life sciences capabilities. The company's confidence in Scotland is testament to the country's global reputation in the sector and we look forward to continuing to work closely with the REPROCELL team to help them realise their growth ambitions."



Photo: Daisuke Matsunaga, Consul General of Japan in Edinburgh, Scotland, with Nicola Sturgeon, First Minister of Scotland and Dr. David Bunton, CEO REPROCELL Europe Ltd. at the official opening of the Centre for Predictive Drug Discovery, REPROCELL Europe Ltd. For a high resolution image please contact lorna.cuddon@zymecommunications.com.

Media Contacts:

Dr. David Bunton, CEO REPROCELL Europe Ltd
david.bunton@reprocell.com
+44 141 465 3460

Lorna Cuddon, Zyme Communications
Lorna.cuddon@zymecommunications.com
+44 (0)7811996942

About REPROCELL Europe — REPROCELL Europe was created on the 1st of July 2016 from the merger of Biopta Ltd and Reinnervate Ltd. REPROCELL Europe offers the full range of life sciences research products and contract research services of the REPROCELL Group Brands (REPROCELL, Biopta, Reinnervate, Stemgent and BioServe) to markets worldwide. Through the ongoing research and development synergies within the Group, REPROCELL Europe aims to bring to market further unique products and services to accelerate research in stem cells, drug discovery, human tissues and 3D cell culture.

About REPROCELL — Headquartered in Yokohama (Japan), REPROCELL is an integrated research and medical company. Serving the global market, the REPROCELL Discovery business unit is focused on providing drug discovery services and products including human tissues and cutting-edge iPS stem cell technologies. Leveraging this history and strength, the REPROCELL Medical business unit (*formed 2017*) is pioneering stem cell-based applications for regenerative medicine therapies and human diagnostics. REPROCELL (<https://reprocell.com>) is a public company traded on the JASDAQ market. For more information on this press release contact your regional REPROCELL office (phone numbers and e-mails provided on the website listed above).

Follow us on social media:

Facebook: <https://www.facebook.com/REPROCELLglobal>
Twitter: <https://twitter.com/REPROCELLglobal>
LinkedIn: <https://www.linkedin.com/company/reprocell/>